This randomized, open-label, multicenter trial evaluates the efficacy and safety of the AI-based lifestyle guidance system (X-Life) compared to standard care in adults with type 2 diabetes. X-Life integrates glucose level, wearable devices, and AI-driven decision models to provide personalized lifestyle recommendations. The primary endpoint is the percentage of time in glucose target range (TIR).
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-31; most recent amendment 2026-02-10.
Status change: Recruiting → Completed2026-02-08
Status change: Not Yet Recruiting → Recruiting2025-09-08